HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Santini, S. A. Articles by Zuppi, C. Search for Related Content PubMed PubMed Citation Articles by Santini, S. A. Articles by Zuppi, C. Related Collections Endocrinology and Metabolism

Assessment of Parathyroid Function in Clinical Practice: Which Parathyroid Hormone Assay Is Better?

¹ Institute of Biochemistry and Clinical Biochemistry, Hormone Research Unit, and² Institute of Surgical Clinic, Hemodialysis Unit, Catholic University School of Medicine, Rome, Italy

^aaddress correspondence to this author at: Institute of Biochemistry and Clinical Biochemistry, Catholic University School of Medicine, Largo F. Vito 1, 00168 Rome, Italy; fax 039-6-30151918, e-mail czuppi@rm.unicatt.it

The first 300 words of the full text of this article appear below.

Parathyroid hormone (PTH) is a single-chain 84-amino acid polypeptide synthesized by the parathyroid glands. In the blood it is thought to circulate as a mixture of whole molecule [PTH (1–84)] and N- and C-terminal (C-PTH) fragments produced in the parathyroid glands and liver (1)(2). In patients with intact renal function, the non-(1–84) PTH, identified by HPLC, reportedly accounts for 21% of PTH(1–84) in hypercalcemia and 10% in hypocalcemia (3). C-PTH fragments accumulate in renal failure up to 40–50% of total PTH (4) and may be implicated in the PTH resistance observed in these patients. It is not known whether these fragments can mimic the biological effects of PTH(1–84) or, in contrast, react with distinct receptors (5)(6)(7)(8).

The major large C-PTH fragment with partially preserved N-terminal structure is PTH(7–84), often considered to be the likely cross-reacting peptide in "intact PTH" (I-PTH) assays (6)(7)(8)(9). The biological activity of this fragment is not definitively known (10)(11)(12)(13). The large increase of C-PTH fragments in renal failure may complicate monitoring of patients (14)(15).

Determination of PTH has also been reported as predictive of different forms of renal osteodystrophy (14). In most laboratories, I-PTH assays from several manufacturers are routinely performed, although the cutoff for PTH concentrations in the classification of adynamic bone in dialysis patients is still controversial (5)(6)(7). These assays use antibodies against amino acids 15–34 and 50–65 of the PTH molecule and, thus, also measure C-PTH fragments with preserved N-terminal structure [such as PTH(7–84)]. A newly available (Bio-Intact) PTH assay measures only the "whole" molecule (residues 1–84) because the . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				R. L. Fitzgerald, D. J. Hillegonds, D. W. Burton, T. L. Griffin, S. Mullaney, J. S. Vogel, L. J. Deftos, and D. A. Herold 41Ca and Accelerator Mass Spectrometry to Monitor Calcium Metabolism in End Stage Renal Disease Patients Clin. Chem., November 1, 2005; 51(11): 2095 - 2102. [Abstract] [Full Text] [PDF]